Considering the two prevalent alterations, KRAS and PIK3CA mutations were more or less equally distributed among the different patients’ subsets, and no statistically significant correlation with sex, onset age (though patients with older age at diagnosis and a higher tumour grade are more likely to present with a PIK3CA mutation), disease stage, primary CRC location, or tumour grading was observed (see Table 1). Here, KRAS is linked to neoplasm.